CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 93 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $375,000 | -3.8% | 31,092 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $390,000 | -0.8% | 31,092 | +17.4% | 0.00% | – |
| Q3 2018 | $393,000 | -11.9% | 26,492 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $446,000 | -26.5% | 26,492 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $607,000 | -15.6% | 26,492 | -4.7% | 0.00% | 0.0% |
| Q4 2017 | $719,000 | +75.4% | 27,792 | 0.0% | 0.00% | – |
| Q3 2017 | $410,000 | +5.7% | 27,792 | 0.0% | 0.00% | – |
| Q2 2017 | $388,000 | -18.1% | 27,792 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $474,000 | +65.7% | 27,792 | 0.0% | 0.00% | – |
| Q4 2016 | $286,000 | +1.8% | 27,792 | 0.0% | 0.00% | – |
| Q3 2016 | $281,000 | -9.9% | 27,792 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $312,000 | -10.3% | 27,792 | +5.7% | 0.00% | 0.0% |
| Q1 2016 | $348,000 | +22.1% | 26,292 | +75.3% | 0.00% | 0.0% |
| Q4 2015 | $285,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 1,050,124 | $10,312,000 | 3.31% |
| Alambic Investment Management, L.P. | 19,934 | $196,000 | 2.15% |
| INGALLS & SNYDER LLC | 1,363,603 | $13,391,000 | 0.92% |
| ACUTA CAPITAL PARTNERS, LLC | 300,000 | $2,946,000 | 0.80% |
| RA Capital Management | 1,858,474 | $18,250,000 | 0.33% |
| Perceptive Advisors | 2,150,641 | $21,119,000 | 0.31% |
| SPHERA FUNDS MANAGEMENT LTD. | 310,000 | $3,044,000 | 0.30% |
| Eversept Partners, LP | 103,829 | $1,019,601 | 0.23% |
| Opaleye Management Inc. | 100,000 | $982,000 | 0.19% |
| GSA CAPITAL PARTNERS LLP | 58,095 | $570,000 | 0.10% |